Can-Fite BioPharma Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Can-Fite BioPharma disminuyan a un ritmo anual de 3.5%, mientras que se prevé que sus ingresos anuales crezcan a un ritmo anual de 2.2%.

Información clave

-3.5%

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	2.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	02 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:CANF - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1	-8	N/A	N/A	1
12/31/2025	1	-7	N/A	N/A	1
12/31/2024	1	-7	N/A	N/A	1
12/31/2023	1	-8	-8	-8	N/A
9/30/2023	1	-9	N/A	N/A	N/A
6/30/2023	1	-10	-10	-10	N/A
3/31/2023	1	-10	N/A	N/A	N/A
12/31/2022	1	-10	-11	-11	N/A
9/30/2022	1	-14	N/A	N/A	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-16	N/A	N/A	N/A
12/31/2021	1	-15	-10	-10	N/A
9/30/2021	1	-12	N/A	N/A	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	N/A	N/A	N/A
12/31/2020	1	-15	-12	-12	N/A
9/30/2020	1	-13	N/A	N/A	N/A
6/30/2020	2	-17	-14	-14	N/A
3/31/2020	2	-13	N/A	N/A	N/A
12/31/2019	2	-13	-11	-11	N/A
9/30/2019	2	-11	N/A	N/A	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	N/A	N/A	N/A
12/31/2018	4	-7	-4	-4	N/A
9/30/2018	4	-5	N/A	N/A	N/A
6/30/2018	2	-6	-5	-5	N/A
3/31/2018	1	-5	N/A	N/A	N/A
12/31/2017	1	-6	-9	-9	N/A
9/30/2017	1	-6	N/A	N/A	N/A
6/30/2017	0	-9	N/A	-9	N/A
3/31/2017	0	-7	N/A	N/A	N/A
12/31/2016	0	-8	N/A	-9	N/A
9/30/2016	0	-5	N/A	N/A	N/A
6/30/2016	0	-6	N/A	-8	N/A
3/31/2016	0	-6	N/A	N/A	N/A
12/31/2015	0	-6	N/A	-5	N/A
9/30/2015	0	-7	N/A	N/A	N/A
6/30/2015	0	-5	N/A	-5	N/A
3/31/2015	N/A	-5	N/A	N/A	N/A
12/31/2014	N/A	-6	N/A	-7	N/A
9/30/2014	N/A	-7	N/A	N/A	N/A
6/30/2014	N/A	-8	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	N/A	N/A
12/31/2013	N/A	-8	N/A	-9	N/A
9/30/2013	N/A	-7	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CANF siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CANF siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CANF siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2.2% al año) de CANF crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.2% al año) de CANF crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CANF se prevé que sea elevada dentro de 3 años.

Can-Fite BioPharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel

Can-Fite Biopharma Ltd. Announces It Is Developing A Topical Psoriasis Treatment with Piclidenoson, Its Phase III Psoriasis Oral Drug Candidate

Can-Fite BioPharma Ltd. Announces Top Line Data from its Phase III Comfort™ Study of Piclidenoson in Treatment of Moderate-To-Severe Plaque Psoriasis to Be Release in the Second Quarter of 2022

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Can-Fite BioPharma Ltd. Announces Pre-Clinical Studies with Skin Cells, Modeling Psoriasis in Humans

Can-Fite Biopharma Ltd Files Patent Applications for the Treatment of Various Advanced Solid Tumors

Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Can-Fite Biopharma Ltd. Announces Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January

Can-Fite Biopharma Ltd. Commences Clinical Study for the Treatment of Canine Osteoarthritis

Can-Fite BioPharma Ltd. Completes Patient Enrollment in Phase III Psoriasis Study

Can-Fite BioPharma Ltd Receives Notice of Patent Allowance in China for NASH Treatment

Can-Fite Biopharma Ltd. to Initiate Phase IIb Nash Study with its Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. Provides Clinical Update

Can-Fite Biopharma Ltd. Announces That 75% of Patients Enrolled in Its Phase III Comfort Study

Can-Fite BioPharma Ltd. Announces New Data from Preclinical Study of Its Drug Candidate CF602 in the Treatment of Erectile Dysfunction in Diabetes Experimental Model

Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

Can-Fite Biopharma Ltd. Announces New Data from the Phase Ii Advanced Liver Cancer Study

Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

Can-Fite BioPharma Ltd Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

Can-Fite Biopharma Ltd. Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs

Can-Fite BioPharma Ltd. Announces Namodenoson Drug Candidate for Non-Alcoholic Steatohepatitis Treatment

Can-Fite BioPharma Ltd., Annual General Meeting, Dec 09, 2020

Can-Fite BioPharma Ltd. to Report Q3, 2020 Results on Nov 30, 2020

Can-Fite Biopharma Ltd. Announces That Dr. Rifaat Safadi, Principal Investigator of the Company's Phase Ii Study of Namodenoson in the Treatment of Nafld/Nash Delivered A Late-Brweaking Oral Presentation At the Aasld Conference

Can-Fite BioPharma Ltd. Announces Positive Phase III Psoriasis Interim Data Analysis

Can-Fite BioPharma Ltd. to Report Q2, 2020 Results on Aug 27, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento